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Grepafloxacin is a new broad-spectrum fluoroquinolone characterized by having a methyl-substituted piperazine at the 
7 position. It is a water-soluble racemate with both stereoisomers having the same activity. Its mode of action involves 
inhibition of topoisomerases II and IV. Grepafloxacin is not recognized by the NorA efflux mechanism in Staphylococcus 
aureus and, thus, some strains of Staphylococcus aureusthat are resistant to other fluoroquinolones remain susceptible 
to grepafloxacin. 
Grepafloxacin has potent in vitro activity against streptococci and staphylococci, respiratory Gram-negative pathogens, 
atypical respiratory pathogens and sexually transmitted disease pathogens. It combines the positive properties of the 
p-lactams against conventional Gram-positive and Gram-negative respiratory pathogens with the activity of the 
macrolides against the atypical pathogens. Unlike macrolides, it is bactericidal at concentrations close to the MIC. Its 
in vitro activity has been reflected in animal models of respiratory tract infections. Concentrations above MlCs are 
maintained throughout nearly al l  of the 24-h dosing interval. Grepafloxacin provides important improvements over older 
quinolones and over other classes of antibiotics. 
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MODE OF ACTION 
Grepafloxacin is a water-soluble fluoroquinolone, 
characterized by a methyl group at the 5 position a 
methyl-substituted piperazine at the 7 position (Figure 
l), which provides some of its unique properties [l]. In 
common with other fluoroquinolones, grepafloxacin’s 
primary target in most organisms is topoisomerase 
I1 (DNA gyrase). It is a selective inhibitor of this 
enzyme, with up to 1000-fold selectivity compared to 
the mammalian enzyme [2,3] (Table 1). Preliminary 
evidence shows that fluoroquinolone targets in Strepto- 
coccus pneumoniae differ according to the compound and 
that the topoisomerase I1 and IV enzymes are mediated 
by thegyrA/B andparC/E genes respectively. Thus, like 
sparfloxacin, grepafloxacin may also target topoisomerase 
11, unlike ciprofloxacin, which primarily targets topo- 
isomerase IV [4]. 
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Grepafloxacin is a racemate, but the stereoisoiners 
are equally active and their safety profiles do not 
differ (Glaxo Wellcome, data on file). Thus, there is 
no advantage in separating the two isomers. 
FLUOROQUINOLONE RESISTANCE 
Grepafloxacin is not recognized by the NorA efflux 
mechanism in Staphylococcus aureus (Hooper, this supple- 
ment). Thus, organisms or strains of Staphylococcus aureus 
that are resistant to quinolones as a result of the NorA 
efflux mechanism remain susceptible to grepafloxacin. 
Pan and Fisher have isolated two series of Strepto- 
coccus pneumoniae mutants; the C series, which is 
resistant to ciprofloxacin, and the S series, which is 
resistant to sparfloxacin. They found that there was a 
two-step mutation process [4]. With ciprofloxacin, a 
modest increase in MIC was associated with a mutation 
in the parC gene-i.e., in topoisomerase IV-while 
the second step, which gave a much enhanced increase 
in the MIC, was due to a second mutation in the 
DNA gyrase gene, gyrA. Conversely, when the 
mutants were selected on sparfloxacin, the first-stage 
mutation-giving a modest increase in MIC-was due 
to a mutation in the DNA gyrase gene, and a double 
mutation gave a large increase in MIC (or increase 
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Table 1 Inhibition of bacterial [2] and calf [3] 
topoisomerase 11-induced DNA supercoiling by 
grepafloxacin and other fluoroquinolones 
Staphylococcus 
unrms SA113 Grepafloxacin 
Ciprofloxacin 
Ofloxacin 
Nodoxacin 
Esilicricliiu 
coli KL-16 Grepafloxacin 
Ciprofloxacin 
Ofloxacin 
Norfloxacin 
C a l i  Grepafloxacin 
Ciprofloxacin 
Ofloxacin 
Norfloxacin 
0.05 23.0 
0.4 20.5 
0.4 27.0 
0.8 91.5 
0.02j 0.19 
0.0125 0.11 
0.0.5 0.48 
0.05 0.33 
- > 100 
> 100 
> 4UO 
> 100 
- 
- 
- 
CH, 0 
A 
Figure 1 The structure of grepafloxacin, a water-soluble 
fluorinated quinolone. 
in resistance). Fisher’s interpretation is that in Strepto- 
coccus pneumoniae, unlike other bacteria, the primary 
target for ciprofloxacin is topoisomerase IV, while for 
sparfloxacin the primary target is DNA gyrase. 
We have tested the activity of grepafloxacin against 
,yyrA and parC mutants kindly provided by Fisher. 
There is no sipficant increase in MIC with either a 
parC or gyA mutation. A two-step mutation is needed 
for high-level resistance to grepafloxacin to be acquired 
(MIC increase greater than 32-fold). It has been 
concluded that both parC andgyrA are equally sensitive 
to grepafloxacin, and this may explain why it was found 
impossible, at least with any reasonable frequency, to 
isolate mutants resistant to grepafloxacin [5]. Mutants 
resistant to ciprofloxacin could be isolated, but these 
were not resistant to grepafloxacin. The generation of 
mutation from single-step mutants to full resistance to 
grepafloxacin is currently being investigated. 
MICROBIOLOGICAL ACTIVITY 
Activity against respiratory tract infections 
Grepafloxacin is being developed predominantly for 
the treatment of community-acquired respiratory tract 
infections. Some studies have been performed in 
sexually transmitted diseases, but the focus of this paper 
is on the activity relevant to respiratory tract pathogens. 
Grepafloxacin has good activity against Streptococcus 
pneurnoniae [6-81 and Staphylococcus aureus [9], the 
Gram-negative pathogens, Haemophilus inzuenzae 
[8,10] and Moraxella catarrlzulis [9], and also against 
the atypical respiratory pathogens [ll-131 (Table 2). It 
is active against Gram-negative organisms, including 
Escherichia coli, Klebsiellu and a range of other entero- 
bacteriaceae (Table 3) [9,11,14,15]. The activity against 
Pseudomonas is variable [9] .  
Grepafloxacin has poor activity against anaerobe$ 
[16], a characteristic which provides some potential 
advantages in terms of lack of effect on fecal flora. 
Gram-positive organisms 
Studies carried out in the USA and Japan on large 
numbers of strains of Gram-positive pathogens show 
similar results with respect to MICsos. The com- 
pound has good activity against Streptococcus pneumoniae, 
Staphylococcirs aureus, Staphylococcus epidermidis and some 
other streptococci, but it is not very active against the 
enterococci [I 71. The MICs for grepafloxacin against 
Streptococcus yneumoniue are, on average, about eight- 
fold lower than for ciprofloxacin and considerably 
lower than for fleroxacin (Figure 2) [7]. 
Penicillin-resistant pneumococci 
Penicillin-resistant pneumococci are becoming in- 
creasingly prevalent worldwide [ 181. The frequency 
Table 2 Microbiological activity of grepafloxacin against 
common respiratory pathogens 
Organism Grepafloxacin Ciprofloxacin 
Gram-positive pathogens 
Streptococcus pneumoniae [8] 0.25 2 
Staphylococcus aurenz [9] 0.12 1 .(I 
Cram-negative pathogens 
Haemophilus inflirenzue [R] 0.008 0.015 
Moraxellu rufurrhalis [9] 0.01 5 5 0.03 
Intracellular respiratory pathogem 
Mycoplasma pneirmoniae [l 11 0.25 2.0 
Chlamydia prrrnrrioniae [12] CJ.06’ 1 . 0 a  
Legionella pneumophila [ 131 10.016 0.03 
‘These values are MIC, not MICsa as only one strain was tested 
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Table 3 Activity of grepafloxacin against other 
microorganisms 
Organism 
MIC9o (mg/L) 
Grepafloxacin Ciprofloxacin 
Enterobacteriaceae 
Escherichia coli [9] 0.03 50.03 
Klebsiella pneumoniae [9] 0.25 0.25 
Pseudomonas aeruginosa [9] 4.0 2.0 
STD pathogens 
Neisseria gonorrhoeae 1141 0.008 0.008 
Chlamydia frachomatis [15] 0.12 - 
Ureaplasma urealyticum [ l l ]  2.0 16 
Anaerobes 
Bacferoides jagilis [16] 8.0 16 
distribution of grepafloxacin MICs has been studied 
against 698 isolates of Streptococcus pneumoniae that had 
been characterized as either penicillin susceptible, 
intermediate or highly resistant [7]. Over 90% had a 
grepafloxacin MIC of 0.25 mg/L or below, irrespective 
of their penicillin sensitivity. This finding has recently 
been confirmed with fresh clinical isolates from Europe 
16,191. 
Gram-negative organisms 
The activity of grepafloxacin against Gram-negative 
organisms is comparable to that of ciprofloxacin 
against H. injuenzae, M .  catarrhalis [8] and the Entero- 
bacteriaceae, e.g. Klebsiella pneumoniae and Enterobacter 
cloacae [9]. Ofloxacin is slightly less active against these 
organisms [2,9]. P-Lactamase-resistant and -sensitive 
strains of H. injuenzae and M. catarrhalis are equally 
susceptible to grepafloxacin [8]. 
lntracellular respiratory pathogens 
There is good activity of grepafloxacin against the 
intracellular or atypical pathogens, Mycoplasma, Chlamydia 
and Legionella spp. A recent study has shown that five 
isolates of Chlamydia pneumoniae were sensitive to 
grepafloxacin, which had a mean MIC of 0.12 mg/L 
[15]. C. trachomatis was also very sensitive to grepa- 
floxacin, with an MIC90 of 0.06 mg/L [15]. 
There are published data on the activity of grepa- 
floxacin against 104 isolates of Legionella spp., mainly 
Legionella pneumophila (97 strains); grepafloxacin showed 
excellent activity, with an MICso of 0.015 mg/L (range 
0.008-0.03) 1151. 
Effects of serum, inoculum, pH, COZ, Mg2+ and 
postantibiotic effect 
Grepafloxacin is bactericidal at a concentration more or 
less equivalent to the MIC 1201, and this activity is not 
influenced by the presence of 50% serum [14]. It  is 
rapidly bactericidal [20] and relatively weakly protein 
bound, and no increase in MIC in the presence of 
serum would be expected. There is a small inoculum 
effect. A lo4 increase in inoculum size results in a 
doubling of the MIC [20]. The effects of pH and COz 
on activity were minimal, but magnesium supple- 
mentation reduced activity 2-4-fold, in common with 
other quinolones 1201. Grepafloxacin has a postanti- 
biotic effect, with suppression of growth continuing 
for 1.6-2.5 h with Escherichia coli, Enterococcus faecalis, 
I? aeruginosa and Staphylococcus aureus following removal 
of the antibiotic 1211. 
ACTIVITY IN ANIMAL MODELS 
Grepafloxacin has been studied in a range of animal 
models of infection. In a murine model of pneumonia 
induced by Streptococcus pneumoniae, untreated control 
G repafloxacin Ciprofloxacin Fleroxacin 
I2O 1 
0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 
MIC (mg/L) 
Figure 2 Cumulative susceptibility of Streptococcus pneumoniae to quinolones. Adapted from Fuchs et al [7 ] .  
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animals had about 10* bacteria per lung [22]. Grepa- 
floxacin, at 8 mg per mouse, completely eliminated the 
bacteria and sterilized the lung, in contrast to ofloxacin 
and ciprofloxacin (Figure 3). 
In a model of H. injuenzae lung infection in 
neutropenic rats, untreated control animals had about 
10’ organisms per lung. A single dose of either 1 mg/kg 
or 2 mg/kg of grepafloxacin caused an almost three- 
log reduction in the number of organisms in the 
lung (Figure 4) [23]. Grepafloxacin is more active in 
this model than ciprofloxacin and ofloxacin, which 
were substantially less effective at  reducing bacterial 
load. 
ACTIVITY IN HUMANS 
Figure 5 shows the mean steady-state plasma levels 
after two doses of grepafloxacin, 400 and 600 mg, in 
male volunteers [24]. The MIC90s for the pathogens 
Streptococcus pneumoniae, H .  injuenzae, C. trachomatis 
and M.  catarrhalis are shown. Even at 400 mg, the 
plasma concentration of grepafloxacin remains above 
the MIC9o for Streptococcus pneumoniae for almost the 
whole of the dosing interval. The predictive value in 
clinical efficacy of the pharrnacokinetidpharmaco- 
dynamic parameters is discussed in the paper by R. 
Wise in this supplement. 
SUMMARY 
Grepafloxacin’s antibacterial spectrum encompasses 
the Gram-positive and Gram-negative coverage of the 
second-generation cephalosporins and the atypical 
coverage of the macrolides with bactericidal action 
in a once-daily dosage regimen. Thus, grepafloxacin 
is active against all the common bacterial pathogens 
responsible for community-acquired respiratory tract 
infections. It  is bactericidal, and its activity is not 
P 1 Grepafloxacin Ofloxacin 0 Ciprofloxacin 
3 - 
Control 0.5 mglmouse 2 mglmouse 8 mglmouse 
x 3 days x 3 days x 3 days 
Figure 3 Effect of grepafloxacin and other quinolones in a murine model of pneumonia caused by Streptococcus pnecrriioniae 
(n=6 in each group). Based on Wakebe H. et a1 (221. 
Control 1 mglkg 2 mglkg 
Grepafloxacin Ciprofloxacin Ofloxacin 
Figure 4 Activity of grepafloxacin and other quinolones in a neutropenic rat lung infection induced by Haemophilir< 
influenzae. Based on Ohmori et a1 1231. 
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Figure 5 Comparison of mean steady-state plasma levels of grepafloxacin, 400- and 600-mg doses, in male volunteers with 
MIC90 values of pathogens of interest. Based on Efthymiopoulos et al [24]. 
affected by the presence of serum or plasma proteins. 
There is a marginal inoculum effect, and little effect 
with pH, C02 or magnesium supplementation. There 
is a postantibiotic effect which is similar to that 
observed with other quinolones [21]. 
The activity of grepafloxacin against conventional 
Gram-positive and Gram-negative respiratory pathogens 
is equivalent to that of a p-lactam antibiotic. However, 
penicillin-resistant pneumococci are equally susceptible 
to grepafloxacin, as are p-lactam-resistant strains of 
H .  infuenzae and M .  catarrhalis. In common with 
the macrolides, grepafloxacin is highly active against 
atypical respiratory pathogens. The properties of this 
compound are ideally suited for the treatment of 
community-acquired respiratory tract infections. 
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